CHASE LABS NJ
GenericsCHASE LABS NJ is a generic drug manufacturer focused on Cardiovascular.
CHASE LABS NJ's Key Drugs
CHASE LABS NJ's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CHASE LABS NJ's Recent FDA Approvals
New NDA/BLA approvals for CHASE LABS NJ over the last two years — novel drugs only, excluding generics and label supplements.
CHASE LABS NJ's Therapeutic Areas
CHASE LABS NJ's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHASE LABS NJ's Top Competitors
CHASE LABS NJ's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHASE LABS NJ Pipeline Snapshot
Active clinical trials for CHASE LABS NJ across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1989-07-10
- Latest
- 1992-08-06
- Applications
- 2